Advertisement
UK Markets close in 1 hr 36 mins
  • FTSE 100

    8,440.63
    +59.28 (+0.71%)
     
  • FTSE 250

    20,678.80
    +147.50 (+0.72%)
     
  • AIM

    789.56
    +5.86 (+0.75%)
     
  • GBP/EUR

    1.1619
    +0.0008 (+0.07%)
     
  • GBP/USD

    1.2537
    +0.0013 (+0.1015%)
     
  • BTC-GBP

    50,289.20
    +1,490.23 (+3.05%)
     
  • CMC Crypto 200

    1,303.49
    -54.52 (-4.02%)
     
  • S&P 500

    5,236.71
    +22.63 (+0.43%)
     
  • DOW

    39,544.82
    +157.06 (+0.40%)
     
  • CRUDE OIL

    79.82
    +0.56 (+0.71%)
     
  • GOLD FUTURES

    2,371.20
    +30.90 (+1.32%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,783.13
    +96.53 (+0.52%)
     
  • CAC 40

    8,233.06
    +45.41 (+0.55%)
     

Label Expansion May Boost Cabometyx’s Revenue in 2018

Label Expansion May Boost Cabometyx’s Revenue in 2018

On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial highlighting the statistically significant and clinically meaningful improvement in the trial’s primary end point of overall survival due to cabozantinib therapy compared to a placebo in second-line and third-line hepatocellular carcinoma (or HCC) patients.